“Taxonomy3(R)” is a human genetics analysis platform that utilises a unique mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases. “Conformetrix” determines the 3D shape of drug molecules from experimental in vitro data giving medicinal chemists new and unprecedented insights into the behaviour and physical properties of drug molecules. This enables the rapid design and discovery of better and safer drugs for diseases with high unmet medical need across broad therapeutic areas. C4X Discovery’s drug discovery engine was further strengthened by the acquisition of technologies from Molplex Ltd, in 2016, which included a software-based system which combines chemoinformatics, computational chemistry and artificial intelligence to optimise the drug discovery process. The Company was founded as a spin-out from the University of Manchester and has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically. For additional information please go to: www.c4discovery.com Read More ABOUT EVOTEC AG Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. read hereWe operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Recommended ReadingEvotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer’s disease, with Sanofi in the field of diabetes and with Pfizer in the field of tissue fibrosis.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/evotec-enters-strategic-multi-target-060000854.html
26, 2016 at 07:46 p.m. Updated: Sept. 26, 2016 at 11:20 p.m. Friend(s) Email More Columns > Carolina Panthers first-round defensive tackle Vernon Butler will miss the next two to three weeks because of a high-ankle sprain, a source informed of the injury told NFL Network Insider Ian Rapoport on Monday. Butler was wearing a cast on his right foot Monday, Rapoport added. He suffered the injury in the second half of Carolina’s 22-10 loss to the Vikings on Sunday while tackling Minnesota tailback Jerick McKinnon . The rookie has accumulated one sack and three tackles over the team’s first three games. Butler, a collegiate defensive standout at Louisiana Tech, was the No. 30 selection in the 2016 NFL Draft . Carolina’s defensive interior has been a strength so far this season, a group that features Butler, Kawann Short and Star Lotulelei .
For the original version including any supplementary images or video, visit http://www.nfl.com/news/story/0ap3000000710511/article/panthers-rookie-vernon-butler-ankle-out-23-weeks